Compare Crispr Therapeutics AG (CRSP) vs Kraft Heinz Co (KHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Kraft Heinz Co — how do they compare? Crispr Therapeutics AG trades at $53.82 (market cap $5.23B), while Kraft Heinz Co trades at $24.31 (market cap $29.23B). The key difference: Kraft Heinz Co is far larger — about 5.6× Crispr Therapeutics AG's market cap, and Kraft Heinz Co pays a 6.49% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | KHC | |
|---|---|---|
Market Cap | $5.23B | $29.23B |
Sector | Health | Consumer Staples |
52-Week High | $76.78 | $28.06 |
52-Week Low | $44.34 | $21.21 |
Enterprise Value | $3.65B | $45.55B |
Dividend Yield | — | 6.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Kraft Heinz (KHC) trades at $24.93, down 1.54% on the day, with a bearish technical signal and mixed fundamentals. The company reported three consecutive quarterly earnings beats but faces profitability challenges with a negative net income margin of -13.64% and ROE of -8.78%. Recent news highlights CEO Steve Cahillane's turnaround strategy with increased marketing investments, while analysts remain cautious with only 11.43% buy ratings.
The stock presents a value opportunity with attractive valuation ratios (P/E 13.04, P/B 0.81) and 6.4% dividend yield, but significant risks include ongoing earnings erosion, competitive pressures, and high debt levels. The consensus price target of $24.00 suggests limited upside from current levels, requiring careful monitoring of the company's execution on its growth strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
